Kura Oncology (KURA) Enterprise Value (2010 - 2026)
Kura Oncology (KURA) posted quarterly Enterprise Value of -$580.8 million for Q1 2026, up 11.75% year-over-year from -$519.7 million in Q1 2025, and up 12.95% quarter-over-quarter from -$667.2 million in Q4 2025.
Kura Oncology (KURA) Enterprise Value (2010 - 2026) Analysis & Trends
Kura Oncology (KURA) has reported Enterprise Value for 17 consecutive years, with -$580.8 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Enterprise Value rose 11.75% year-over-year to -$580.8 million; the TTM figure through Mar 2026 stood at -$580.8 million (up 11.75% YoY), while the FY2025 annual figure was -$667.2 million, up 8.27% from the prior year.
- Enterprise Value rose to -$580.8 million in Q1 2026 per KURA's latest filing, from -$667.2 million in the prior quarter.
- Across five years, Enterprise Value topped out at -$405.9 million in Q1 2023 and bottomed at -$727.4 million in Q4 2024.
- Historically, Enterprise Value has averaged -$520.2 million across 5 years, with a median of -$480.1 million in 2022.
- Annual changes were most pronounced in 2022 — Enterprise Value climbed 21.28% — and 2024, when it slumped 71.57%.
- Kura Oncology's Enterprise Value stood at -$438.0 million in 2022, then rose by 3.2% to -$424.0 million in 2023, then plunged by 71.57% to -$727.4 million in 2024, then rose by 8.27% to -$667.2 million in 2025, then advanced by 12.95% to -$580.8 million in 2026.
- Business Quant data shows KURA's Enterprise Value at -$580.8 million in Q1 2026, -$667.2 million in Q4 2025, and -$549.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | -5.18 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -3.94 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -5.10 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -8.46 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 2.12 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -3.31 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.16 Bn |
| 10 | Kura Oncology | 966.11 Mn | 966.11 Mn | 20.63 Mn | -519.03 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -519.03 Mn |
| Mar 31, 2026 | -580.82 Mn |
| Dec 31, 2025 | -667.24 Mn |
| Sep 30, 2025 | -549.67 Mn |
| Jun 30, 2025 | -630.73 Mn |
| Mar 31, 2025 | -658.19 Mn |
| Dec 31, 2024 | -727.40 Mn |
| Sep 30, 2024 | -455.30 Mn |
| Jun 30, 2024 | -491.52 Mn |
| Mar 31, 2024 | -527.12 Mn |
| Dec 31, 2023 | -423.96 Mn |
| Sep 30, 2023 | -452.59 Mn |
| Jun 30, 2023 | -476.98 Mn |
| Mar 31, 2023 | -405.90 Mn |
| Dec 31, 2022 | -437.99 Mn |
| Sep 30, 2022 | -427.78 Mn |
| Jun 30, 2022 | -450.26 Mn |
| Mar 31, 2022 | -480.08 Mn |
| Dec 31, 2021 | -517.96 Mn |
| Sep 30, 2021 | -543.45 Mn |